Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab

• Published in: Oncogene Vol. 38; no. 18; pp. 3458 - 3474
• Main Authors: Wang, Dawei, Xu, Qingqing, Yuan, Quan, Jia, Mengqi, Niu, Huanmin, Liu, Xiaofei, Zhang, Jinsan, Young, Charles Yf, Yuan, Huiqing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.05.2019; Nature Publishing Group
• Subjects: 38/61; 38/77; 38/89; 42/109; 42/35; 45/70; 631/67/1059/2326; 631/80/474/582; 82/51; 82/79; A549 Cells; Angiogenesis; Animals; Antineoplastic Agents; Antitumor activity; Apoptosis; Autophagy; Autophagy - drug effects; Bevacizumab; Bevacizumab - pharmacology; Bortezomib; Bortezomib - pharmacology; Cancer; Cancer cells; Cell Biology; Cell Line; Cell Line, Tumor; Chemotherapy; Dosage and administration; Gene expression; Gene silencing; Genetic aspects; Human Genetics; Humans; Immunotherapy; Internal Medicine; Kinases; Ligases; Lung cancer; Male; Medical research; Medicine; Medicine & Public Health; Messenger RNA; Mice; Mice, Inbred BALB C; Mice, Nude; Monoclonal antibodies; Oncology; Pancreatic cancer; Phagocytosis; Polyubiquitin - metabolism; Proteasome Endopeptidase Complex - metabolism; Proteasome inhibitors; Proteasome Inhibitors - pharmacology; Protein disulfide-isomerase; Proteins; Proteins - metabolism; Rapamycin; RNA; Targeted cancer therapy; Transcription (Genetics); Tumors; Ubiquitin - metabolism; Ubiquitin-protein ligase; Ubiquitin-Protein Ligases - metabolism; Ubiquitination - drug effects

Anterior gradient 2 (AGR2), a protein belonging to the protein disulfide isomerase (PDI) family, is overexpressed in multiple cancers and promotes angiogenesis to drive cancer progression. The mechanisms controlling AGR2 abundance in cancer remain largely unknown. Here, we observed that AGR2 express...